| |
| |
|
| Insider
Information: |
Machado Clarence Patrick |
| Relationship: |
Director |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
175,082 |
|
|
Indirect Shares
|
185,606,208 |
|
|
| Direct
Value |
$1,141,143 |
|
|
|
Indirect Value
|
$1,576,420,213 |
|
|
| Total
Shares |
185,781,290 |
|
|
| Total
Value |
$1,577,561,355 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
| Percentage
Gain/Loss : |
 -80.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Medivation Inc |
MDVN |
Director |
2016-09-28 |
0 |
2012-02-08 |
0 |
Premium* |
|
|
Endocyte Inc |
ECYT |
Director |
2018-12-21 |
0 |
2018-02-27 |
0 |
Premium* |
|
|
Chimerix Inc |
CMRX |
Director |
2015-12-29 |
10,000 |
2015-12-29 |
0 |
Premium* |
|
|
Scynexis Inc |
SCYX |
Director |
2016-09-15 |
60,000 |
2016-06-24 |
0 |
Premium* |
|
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
|
Tekmira Pharmaceuticals Corp |
TKMR |
10% Owner |
|
0 |
2016-10-18 |
16,013,540 |
Premium* |
|
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
|
Adverum Biotechnologies, Inc |
ADVM |
Director |
2021-03-24 |
88,182 |
2017-03-14 |
0 |
Premium* |
|
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
|
Arcus Biosciences Inc |
RCUS |
Director |
2023-06-15 |
16,900 |
2020-06-04 |
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Director |
2023-10-04 |
0 |
2023-10-04 |
14,675 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MDVN |
Medivation Inc |
Director |
– • – |
2015-02-10 |
4 |
AS |
$101.27 |
$3,739,984 |
D/D |
(36,000) |
31,500 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-02-10 |
4 |
OE |
$9.39 |
$337,860 |
D/D |
36,000 |
67,500 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-06-04 |
4 |
AS |
$116.12 |
$4,227,478 |
D/D |
(36,000) |
31,500 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-06-04 |
4 |
OE |
$9.39 |
$337,860 |
D/D |
36,000 |
67,500 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,578 |
33,078 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-09-25 |
4 |
AS |
$40.82 |
$3,049,106 |
D/D |
(71,980) |
66,156 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2015-09-25 |
4 |
OE |
$4.69 |
$337,766 |
D/D |
71,980 |
138,136 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-01-19 |
4 |
AS |
$36.62 |
$2,800,562 |
D/D |
(75,000) |
66,156 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-01-19 |
4 |
OE |
$3.37 |
$252,525 |
D/D |
75,000 |
141,156 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,972 |
70,792 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-09-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(70,792) |
0 |
0 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
10% Owner |
– – • |
2016-10-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,231,342 |
|
- |
|
| MYOV |
Myovant Sciences Ltd. |
10% Owner |
– – • |
2018-04-02 |
4 |
B |
$20.27 |
$22,500,004 |
I/I |
1,110,015 |
38,341,357 |
1.5 |
- |
|
| MYOV |
Myovant Sciences Ltd. |
10% Owner |
– – • |
2019-06-04 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
40,765,599 |
1.5 |
- |
|
| RCUS |
Arcus Biosciences Inc |
Director |
– • – |
2020-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| RCUS |
Arcus Biosciences Inc |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
6,000 |
0 |
- |
|
| RCUS |
Arcus Biosciences Inc |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,100 |
10,100 |
0 |
- |
|
| RCUS |
Arcus Biosciences Inc |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
16,900 |
0 |
- |
|
| SCYX |
Scynexis Inc |
Director |
– • – |
2016-06-24 |
4 |
B |
$2.39 |
$47,800 |
D/D |
20,000 |
20,000 |
2.39 |
- |
|
| SCYX |
Scynexis Inc |
Director |
– • – |
2016-09-15 |
4 |
B |
$2.94 |
$117,600 |
D/D |
40,000 |
60,000 |
2.39 |
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,000,000 |
|
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2018-06-05 |
4 |
B |
$1.75 |
$25,000,000 |
I/I |
14,285,714 |
89,285,714 |
1.5 |
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2018-12-18 |
4 |
B |
$1.00 |
$10,000,000 |
I/I |
10,000,000 |
99,285,714 |
1.5 |
- |
|
| SIOX |
Sio Gene Therapies Inc |
10% Owner |
– – • |
2019-03-18 |
4 |
B |
$1.50 |
$10,000,001 |
I/I |
6,666,667 |
105,952,381 |
1.5 |
- |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • – |
2023-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
14,675 |
14,675 |
0 |
- |
|
126 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
